LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Rating of “Moderate Buy” by Brokerages

LifeStance Health Group, Inc. (NASDAQ:LFST) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.3750.

Several equities research analysts have issued reports on the company. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. The Goldman Sachs Group assumed coverage on LifeStance Health Group in a research report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Barclays increased their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen upgraded LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $12.65 on Friday. The firm has a market cap of $4.91 billion, a P/E ratio of 97.32 and a beta of 1.14. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average is $10.76 and its 200-day moving average is $8.38. LifeStance Health Group has a 12-month low of $4.77 and a 12-month high of $12.97.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. During the same period last year, the firm earned ($0.01) EPS. LifeStance Health Group’s revenue for the quarter was up 26.1% on a year-over-year basis. Sell-side analysts predict that LifeStance Health Group will post 0.16 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Robert Bessler sold 894,337 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director directly owned 539,763 shares of the company’s stock, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Lisa K. Miller sold 47,912 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the transaction, the chief operating officer owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This trade represents a 14.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 14,629,850 shares of company stock valued at $154,952,012. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in shares of LifeStance Health Group by 63.4% in the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC boosted its stake in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock valued at $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after buying an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after buying an additional 11,331 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in LifeStance Health Group by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock worth $2,847,000 after buying an additional 51,154 shares in the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.